Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Merck
Daiichi Sankyo
Farmers Insurance
Covington
Accenture
Citi
Cantor Fitzgerald

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018891

« Back to Dashboard

NDA 018891 describes CATAPRES-TTS-3, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from two suppliers. Additional details are available on the CATAPRES-TTS-3 profile page.

The generic ingredient in CATAPRES-TTS-3 is clonidine. There are twenty-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clonidine profile page.
Summary for 018891
Tradename:CATAPRES-TTS-3
Applicant:Boehringer Ingelheim
Ingredient:clonidine
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 018891
Mechanism of ActionAdrenergic alpha2-Agonists
Medical Subject Heading (MeSH) Categories for 018891
Suppliers and Packaging for NDA: 018891
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CATAPRES-TTS-1 clonidine FILM, EXTENDED RELEASE;TRANSDERMAL 018891 NDA Boehringer Ingelheim Pharmaceuticals Inc. 0597-0031 N 0597-0031-34
CATAPRES-TTS-1 clonidine FILM, EXTENDED RELEASE;TRANSDERMAL 018891 NDA Boehringer Ingelheim Pharmaceuticals Inc. 0597-0032 N 0597-0032-34

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength0.1MG/24HR
Approval Date:Oct 10, 1984TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength0.2MG/24HR
Approval Date:Oct 10, 1984TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength0.3MG/24HR
Approval Date:Oct 10, 1984TE:ABRLD:Yes

Expired US Patents for NDA 018891

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim CATAPRES-TTS-1 clonidine FILM, EXTENDED RELEASE;TRANSDERMAL 018891-001 Oct 10, 1984 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim CATAPRES-TTS-3 clonidine FILM, EXTENDED RELEASE;TRANSDERMAL 018891-003 Oct 10, 1984 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim CATAPRES-TTS-2 clonidine FILM, EXTENDED RELEASE;TRANSDERMAL 018891-002 Oct 10, 1984 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim CATAPRES-TTS-2 clonidine FILM, EXTENDED RELEASE;TRANSDERMAL 018891-002 Oct 10, 1984 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Citi
Cerilliant
Harvard Business School
US Army
Dow
Chubb
Cantor Fitzgerald
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.